ERBB2 and neoplasm: Factors significantly associated with the occurrence of CNS metastases as the first site of metastatic disease were higher tumor stage before therapy (cT3–4), node-positive disease, HER2-positive or triple-negative subtype, and no pCR after neoadjuvant chemotherapy.